cll1-cd33 ccar t cells
Cell therapyexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2018 (NCT03795779)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Myeloid cell surface antigen CD33Immunity, passive
CD33 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05943314 | N/A | Jul 12, 2023 | Guangzhou Bio-gene Technology Co., Ltd. |
| NCT05467254 | Phase 1 | Aug 2, 2022 | Zhejiang University |
| NCT05248685 | Phase 1 | Jan 17, 2022 | Beijing Boren Hospital |
| NCT05016063 | Early Phase 1 (Phase 1) | Sep 1, 2021 | People's Liberation Army of China, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Xinqiao Hospital of Chongqing |
| NCT03795779 | Early Phase 1 (Phase 1) | Mar 1, 2018 | iCell Gene Therapeutics, Peking University, People's Liberation Army of China |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 2 | 1 | 1 | 2018 |
| Beijing Boren Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Guangzhou Bio-gene Technology Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| iCell Gene Therapeutics | For profit | 1 | 1 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
| Xinqiao Hospital of Chongqing | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
8 organizations
Page 1 / 1